At One Month Post-Launch, More than One-Quarter of Surveyed U.S. Medical Oncologists Have Prescribed Boehringer Ingelheim's Gilotrif for Non-Small-Cell Lung Cancer

Approximately Three-Quarters of Gilotrif Nonprescribers Anticipate Prescribing Gilotrif Within the Next Six Months, According to a New Report from BioTrends Research Group

Dec 09, 2013, 10:23 ET from BioTrends Research Group

EXTON, Pa., Dec. 9, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, one month post-launch in the United States, more than a quarter of surveyed U.S. medical oncologists have prescribed Boehringer Ingelheim's irreversible epidermal growth factor receptor (EGFR) inhibitor Gilotrif for the treatment of non-small-cell lung cancer (NSCLC). According to the first wave of the LaunchTrends® Gilotrif report series, approximately three-quarters of current Gilotrif nonprescribers expect to prescribe Gilotrif to their treatment-naive, EGFR mutation-positive metastatic NSCLC patients within the next six months.

(Logo: )

The report also finds that over half of surveyed medical oncologists reported high favorability towards Gilotrif, and nearly two-thirds indicated a high interest level in learning more about the product. However, Gilotrif fails to significantly differentiate itself from Genentech/Roche/Chugai/Astellas' Tarceva for the treatment of EGFR mutation-positive NSCLC patients in the first-line setting over most key metrics, including efficacy and tolerability attributes. Notably, the availability of Tarceva is one of the top reasons limiting use of Gilotrif in this indication, along with lack of familiarity with Gilotrif and cost.

"We also find that medical oncologists are moderately to highly interested in prescribing Gilotrif in new, additional patient populations and hope to see regulatory approval in these indications, including the EGFR mutation-positive, EGFR TKI pretreated patient population and for patients harboring other EGFR mutations, including those associated with resistance to Tarceva (e.g. T790M mutations)," said Decision Resources Group Business Insights Analyst Orestis Mavroudis-Chocholis, Ph.D. "Similarly, surveyed medical oncologists report that they are most likely to prescribe Gilotrif in these patient populations over other available therapies, including Tarceva and chemotherapy regimens."

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort

SOURCE BioTrends Research Group